Refueling the Failing Heart

Q: What is the clinical evidence from this study?

Study design: Editorial. Population: Type 2 diabetes and heart failure (preclinical model). Intervention: Empagliflozin vs. Vehicle. Primary outcome: ATP production in isolated working hearts (increased by 30%).

Q: What does this research mean for the field?

Empagliflozin increases ATP production by 30% and improves cardiac work in isolated working hearts from db/db diabetic mice. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Peter A. Crawford

doi:10.1016/j.jacbts.2018.08.002

August 26, 2018JACC Basic to Translational ScienceOpen Access

Refueling the Failing Heart

View Full Paper

Ask AI

Bookmark

Share

Graphical abstract published by JACC Basic to Translational Science — Graphical abstract · Published by JACC Basic to Translational Science · CC BY-NC-ND

Why the study?

Does empagliflozin improve cardiac work and ATP production in db/db diabetic mice?

Structured PICO

Does empagliflozin improve cardiac work and ATP production in db/db diabetic mice?

P

Population

An editorial discussing a preclinical study of db/db diabetic mice evaluated for cardiac hemodynamics and energetics following empagliflozin treatment.

I

Intervention

Empagliflozin 10 mg/kg per day mixed with standard chow for 4 weeks

C

Comparator

Vehicle-fed db/db mice

O

Outcome

Cardiac work and ATP production in isolated working heartssurrogate

Main Result

Effect estimate: increased by 30%

Limitations

Absence of a lean control group treated with empagliflozin
Ex vivo perfusion studies used a glucose concentration less than one-half that in the circulation of vehicle-treated db/db animals
Ex vivo perfusion studies used only 5 mM glucose, which is significantly lower than circulating levels in the mice

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

This editorial highlights preclinical evidence that empagliflozin improves cardiac work and energy turnover in insulin-resistant diabetic hearts, independent of changes in myocardial ketone oxidation.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Peter A. Crawford (2018) conducted an editorial in Type 2 diabetes and heart failure (preclinical model). Empagliflozin vs. Vehicle was evaluated on ATP production in isolated working hearts (increased by 30%).

synapsesocial.com/papers/6ac59f854c120b06f283c8ec https://doi.org/10.1016/j.jacbts.2018.08.002

View Full Paper

Ask AI

Bookmark

Share

Refueling the Failing Heart

Structured PICO

Main Result

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Refueling the Failing Heart

Structured PICO

Main Result

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading